Molecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs)

Overview

Journal Theranostics

Date 2012 Jul 7

PMID 22768025

Citations 20

Authors

Kjell Oberg

Affiliations

Soon will be listed here.

Abstract

Neuroendocrine tumors (NETs) possess unique features including expression of peptide hormone receptors as well as the capacity to concentrate and take up precursor forms of amines and peptides making hormones that are stored in secretory granules within the tumor cells (APUD). The expression of somatostatin receptors on tumor cells have been widely explored during the last two decades starting with (111)In-DTPA-Octreotide as an imaging agent followed by (68)Ga-DOTATOC/TATE positron emission tomography scanning. The new generation of treatment includes (90)Yttrium-DOTATOC/DOTATATE as well as (177)Lutetium-DOTATOC/DOTATATE/DOTANOC treatment of various subtypes of NETs. The objective response rate by these types of PRRT is in the range of 30-45% objective responses with 5-10% grade 3/4 toxicity mainly hematologic and renal toxicity. The APUD mechanism is another unique feature of NETs which have generated an interest over the last two decades to develop specific tracers including (11)C-5HTP, (18)F-DOPA and (11)C-hydroxyefedrin. These radioactive tracers have been developed in centres with specific interest in NETs and are not available everywhere. (111)In-DTPA-Octreotide is still the working horse in diagnosis and staging of metastatic NETs, but will in the future be replaced by (68)Ga-DOTATOC/DOTATATE PET/CT scanning which provide higher sensitivity and specificity and is also more convenient for the patient because it is a one-stop-procedure. Both (90)Yttrium-DOTATOC/DOTATATE as well as (177)Lutetium-DOTATOC/DOTATATE are important new therapies for malignant metastatic NETs. However, the precise role in the treatment algorithm has to be determined in forthcoming randomized trials.

Citing Articles

Radiopharmaceuticals and their applications in medicine.

Zhang S, Wang X, Gao X, Chen X, Li L, Li G Signal Transduct Target Ther. 2025; 10(1):1.

PMID: 39747850 PMC: 11697352. DOI: 10.1038/s41392-024-02041-6.

Radiobiological Assessment of Targeted Radionuclide Therapy with [Lu]Lu-PSMA-I&T in 2D vs. 3D Cell Culture Models.

Raitanen J, Barta B, Fuchs H, Hacker M, Balber T, Georg D Int J Mol Sci. 2023; 24(23).

PMID: 38069337 PMC: 10706939. DOI: 10.3390/ijms242317015.

Development of a new quantification method using partial volume effect correction for individual energy peaks in In-pentetreotide SPECT/CT.

Yamashita K, Miyaji N, Motegi K, Terauchi T, Ito S Asia Ocean J Nucl Med Biol. 2022; 10(2):126-137.

PMID: 35800427 PMC: 9205847. DOI: 10.22038/AOJNMB.2022.61394.1430.

Theranostic Advances in Breast Cancer in Nuclear Medicine.

Vahidfar N, Aghanejad A, Ahmadzadehfar H, Farzanehfar S, Eppard E Int J Mol Sci. 2021; 22(9).

PMID: 33925632 PMC: 8125561. DOI: 10.3390/ijms22094597.

PRRT neuroendocrine tumor response monitored using circulating transcript analysis: the NETest.

Bodei L, Kidd M, Singh A, van der Zwan W, Severi S, Drozdov I Eur J Nucl Med Mol Imaging. 2019; 47(4):895-906.

PMID: 31838581 PMC: 7515632. DOI: 10.1007/s00259-019-04601-3.

References

Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P . Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med. 1999; 26(11):1439-47. View

Adams S, Baum R, Rink T, Usadel K, Hor G . Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med. 1998; 25(1):79-83. DOI: 10.1007/s002590050197. View

Krenning E, Bakker W, Kooij P, Breeman W, Oei H, de Jong M . Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992; 33(5):652-8. View

Jacob T, Grahek D, Younsi N, Kerrou K, Aide N, Montravers F . Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results. Eur J Nucl Med Mol Imaging. 2003; 30(9):1266-9. DOI: 10.1007/s00259-003-1249-3. View

Anthony L, Woltering E, Espenan G, Cronin M, Maloney T, McCarthy K . Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med. 2002; 32(2):123-32. DOI: 10.1053/snuc.2002.31769. View

Eriksson B, Bergstrom M, Orlefors H, Sundin A, Oberg K, Langstrom B . Use of PET in neuroendocrine tumors. In vivo applications and in vitro studies. Q J Nucl Med. 2000; 44(1):68-76. View

Kwekkeboom D, Bakker W, Kooij P, Konijnenberg M, Srinivasan A, Erion J . [177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients. Eur J Nucl Med. 2001; 28(9):1319-25. DOI: 10.1007/s002590100574. View

Ahlstrom H, Eriksson B, Bergstrom M, Bjurling P, Langstrom B, Oberg K . Pancreatic neuroendocrine tumors: diagnosis with PET. Radiology. 1995; 195(2):333-7. DOI: 10.1148/radiology.195.2.7724749. View

Kaltsas G, Michael Besser G, Grossman A . The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004; 25(3):458-511. DOI: 10.1210/er.2003-0014. View

10.

Koopmans K, Neels O, Kema I, Elsinga P, Sluiter W, Vanghillewe K . Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. J Clin Oncol. 2008; 26(9):1489-95. DOI: 10.1200/JCO.2007.15.1126. View

11.

Teunissen J, Kwekkeboom D, Krenning E . Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Clin Oncol. 2004; 22(13):2724-9. DOI: 10.1200/JCO.2004.10.016. View

12.

Virgolini I, Britton K, Buscombe J, Moncayo R, Paganelli G, Riva P . In- and Y-DOTA-lanreotide: results and implications of the MAURITIUS trial. Semin Nucl Med. 2002; 32(2):148-55. DOI: 10.1053/snuc.2002.31565. View

13.

Lee D, Li K . Molecular theranostics: a primer for the imaging professional. AJR Am J Roentgenol. 2011; 197(2):318-24. PMC: 3448440. DOI: 10.2214/AJR.11.6797. View

14.

Gazdar A, Helman L, Israel M, RUSSELL E, Linnoila R, Mulshine J . Expression of neuroendocrine cell markers L-dopa decarboxylase, chromogranin A, and dense core granules in human tumors of endocrine and nonendocrine origin. Cancer Res. 1988; 48(14):4078-82. View

15.

Waldherr C, Pless M, Maecke H, Haldemann A, Mueller-Brand J . The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol. 2001; 12(7):941-5. DOI: 10.1023/a:1011160913619. View

16.

Bushnell Jr D, ODorisio T, ODorisio M, Menda Y, Hicks R, Van Cutsem E . 90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol. 2010; 28(10):1652-9. PMC: 4872330. DOI: 10.1200/JCO.2009.22.8585. View

17.

Kwekkeboom D, de Herder W, Kam B, Van Eijck C, Van Essen M, Kooij P . Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008; 26(13):2124-30. DOI: 10.1200/JCO.2007.15.2553. View

18.

Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H . Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011; 29(17):2416-23. DOI: 10.1200/JCO.2010.33.7873. View

19.

Reubi J, Schar J, Waser B, Wenger S, Heppeler A, Schmitt J . Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000; 27(3):273-82. DOI: 10.1007/s002590050034. View

20.

Kowalski J, Henze M, Schuhmacher J, Macke H, Hofmann M, Haberkorn U . Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003; 5(1):42-8. DOI: 10.1016/s1536-1632(03)00038-6. View